LAB Standard BioTools Inc
Price (delayed)
$1.18
Market cap
$447.2M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.52
Enterprise value
$313.47M
Fluidigm focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, it develops, manufactures, and markets multi-omic solutions
Highlights
Standard BioTools's gross profit has soared by 67% YoY and by 11% from the previous quarter
The debt has dropped by 66% year-on-year and by 63% since the previous quarter
The company's net income has shrunk by 86% YoY and by 11% QoQ
Standard BioTools's equity has decreased by 3.6% QoQ
Key stats
What are the main financial stats of LAB
Market
Valuations
Earnings
Shares outstanding
378.99M
Market cap
$447.2M
Enterprise value
$313.47M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.93
Price to sales (P/S)
2.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.8
Revenue
$174.43M
Gross profit
$84.26M
Operating income
-$175.24M
Net income
-$138.89M
EBIT
-$135M
EBITDA
-$112.37M
Free cash flow
-$151.81M
Per share
Balance sheet
Liquidity
EPS
-$0.52
EPS diluted
-$0.52
Free cash flow per share
-$0.43
Book value per share
$1.27
Revenue per share
$0.49
TBVPS
$1.34
Total assets
$612.34M
Total liabilities
$140.62M
Debt
$33M
Equity
$471.72M
Working capital
$309.99M
Debt to equity
0.07
Current ratio
5.7
Quick ratio
4.95
Net debt/EBITDA
1.19
Margins
Efficiency
Dividend
EBITDA margin
-64.4%
Gross margin
48.3%
Net margin
-79.6%
Operating margin
-100.5%
Return on assets
-26.6%
Return on equity
-36.1%
Return on invested capital
-45.5%
Return on capital employed
-24.7%
Return on sales
-77.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LAB stock price
How has the Standard BioTools stock price performed over time
Intraday
8.26%
1 week
-0.84%
1 month
10.8%
1 year
-55.3%
YTD
-32.57%
QTD
9.26%
Financial performance
How have Standard BioTools's revenue and profit performed over time
Revenue
$174.43M
Gross profit
$84.26M
Operating income
-$175.24M
Net income
-$138.89M
Gross margin
48.3%
Net margin
-79.6%
LAB's operating income has plunged by 129% YoY and by 7% from the previous quarter
The company's net income has shrunk by 86% YoY and by 11% QoQ
Standard BioTools's gross profit has soared by 67% YoY and by 11% from the previous quarter
Standard BioTools's revenue has soared by 64% YoY and by 12% from the previous quarter
Growth
What is Standard BioTools's growth rate over time
Valuation
What is Standard BioTools stock price valuation
P/E
N/A
P/B
0.93
P/S
2.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.8
Standard BioTools's EPS has increased by 45% YoY and by 27% from the previous quarter
The price to book (P/B) is 39% lower than the last 4 quarters average of 1.4
Standard BioTools's equity has decreased by 3.6% QoQ
Standard BioTools's revenue has soared by 64% YoY and by 12% from the previous quarter
The P/S is 54% below the last 4 quarters average of 4.8 and 21% below the 5-year quarterly average of 2.8
Efficiency
How efficient is Standard BioTools business performance
The ROE has increased by 24% QoQ
The company's return on assets fell by 24% YoY but it rose by 2.9% QoQ
Standard BioTools's ROS has decreased by 18% YoY
The return on invested capital has declined by 15% year-on-year
Dividends
What is LAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LAB.
Financial health
How did Standard BioTools financials performed over time
LAB's total assets has surged by 90% year-on-year but it is down by 10% since the previous quarter
The current ratio has soared by 52% from the previous quarter
The debt is 93% smaller than the equity
LAB's debt to equity has soared by 111% year-on-year but it has dropped by 61% since the previous quarter
The debt has dropped by 66% year-on-year and by 63% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.